Aspire Biopharma Holdings (ASBP) Income from Continuing Operations (2024 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Income from Continuing Operations came in at 3222892.0 in Q1 2026, up 79.78% year-on-year from 1792658.81 in Q1 2025, and up 60.13% on a QoQ basis from 8082817.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Income from Continuing Operations (2024 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 3 years of Income from Continuing Operations data on file, last reported at 3222892.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 79.78% year-over-year to 3222892.0 in Q1 2026; TTM through Mar 2026 was 29872592.0, a N/A change from a year earlier, with the FY2025 full-year figure at 19339870.0, down 1376.47% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 3222892.0, up from 8082817.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for ASBP reached as high as 216269.0 in Q3 2024 and fell as low as 15941328.0 in Q1 2025.
- Historically, Income from Continuing Operations has averaged 5114083.33 across 3 years, with a median of 2924223.5 in 2025.
- Across the five-year window, Income from Continuing Operations plunged 1257.0% in 2025 and soared 79.78% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 595639.0 in 2024, then plunged by 1257.0% to 8082817.0 in 2025, then soared by 60.13% to 3222892.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 3222892.0 in Q1 2026, 8082817.0 in Q4 2025, and 2625555.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Aspire Biopharma Holdings | 1.21 Mn | -619,284.29 | 5,750.00 | -3.22 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.22 Mn |
| Dec 31, 2025 | -8.08 Mn |
| Sep 30, 2025 | -2.63 Mn |
| Mar 31, 2025 | -15.94 Mn |
| Dec 31, 2024 | -595,639.00 |
| Sep 30, 2024 | -216,269.00 |